Dashboard
Manage Tickers

HOWL Werewolf Therapeutics, Inc.

Nasdaq werewolftx.com


$ 1.59 $ -0.07 (-4.19 %)    

Friday, 17-Oct-2025 16:56:42 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 1.6
$ 1.65
$ 1.55 x 101
$ 1.80 x 1,600
$ 1.58 - $ 1.68
$ 0.60 - $ 4.18
556,186
na
73.17M
$ 1.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-11-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-03-2024 03-31-2024 10-Q
7 03-07-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-23-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-24-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 06-10-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

reported-earlier-werewolf-therapeutics-receives-fast-track-designation-for-the-use-of-wtx-124-for-the-potential-treatment-of-patients-with-locally-advanced-or-metastatic-cutaneous-melanoma-after-standard-of-care-immunotherapy
Reported Earlier: Werewolf Therapeutics Re...
10/08/2025 14:22:06

WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/23/2025 12:09:16

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
09/22/2025 21:06:10

b-of-a-securities-maintains-buy-on-werewolf-therapeutics-lowers-price-target-to-8
B of A Securities Maintains Buy on Werewol...
08/25/2025 16:55:36

B of A Securities analyst Jason Zemansky maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and lowers the price targe...

jmp-securities-maintains-market-outperform-on-werewolf-therapeutics-lowers-price-target-to-3
JMP Securities Maintains Market Outperform...
08/21/2025 13:11:49

JMP Securities analyst Reni J. Benjamin maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and lowers th...

werewolf-therapeutics-q2-eps-040-beats-048-estimate
Werewolf Therapeutics Q2 EPS $(0.40) Beats...
08/14/2025 11:18:12

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of...

patient-with-advanced-skin-cancer-in-remission-over-year-after-clinical-trial-of-werewolf-therapeutics-investigational-novel-conditionally-activated-il-2-pro-drug-wtx-124
Patient With Advanced Skin Cancer In Remis...
05/20/2025 20:03:17

There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to ...

wedbush-maintains-outperform-on-werewolf-therapeutics-lowers-price-target-to-6
Wedbush Maintains Outperform on Werewolf T...
05/09/2025 16:58:51

Wedbush analyst Robert Driscoll maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Outperform and lowers the price target ...

werewolf-therapeutics-q1-eps-040-beats-044-estimate
Werewolf Therapeutics Q1 EPS $(0.40) Beats...
05/08/2025 11:11:11

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of...

werewolf-therapeutics-presents-new-preclinical-data-further-characterizing-its-il-10-indukine-molecule-wtx-921-for-the-treatment-of-inflammatory-bowel-disease-at-aai-annual-meeting
Werewolf Therapeutics Presents New Preclin...
05/05/2025 12:14:33

- Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine pro...

wedbush-reiterates-outperform-on-werewolf-therapeutics-maintains-8-price-target
Wedbush Reiterates Outperform on Werewolf ...
03/12/2025 14:32:39

Wedbush analyst Robert Driscoll reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Outperform and maintains $8 price target.

hc-wainwright--co-reiterates-buy-on-werewolf-therapeutics-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on Were...
03/12/2025 11:30:36

HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15...

werewolf-therapeutics-q4-2024-gaap-eps-046-misses-042-estimate-as-of-december-31-2024-cash-and-cash-equivalents-were-111m-expected-to-provide-cash-runway-into-q2-of-2026
Werewolf Therapeutics Q4 2024 GAAP EPS $(0...
03/11/2025 11:16:28

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate ...

jmp-securities-maintains-market-outperform-on-werewolf-therapeutics-lowers-price-target-to-4
JMP Securities Maintains Market Outperform...
01/14/2025 14:13:20

JMP Securities analyst Reni Benjamin maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and lowers the p...

werewolf-therapeutics-outlines-2025-milestones-sees-phase-11b-results-for-wtx-124-monotherapy-and-combo-with-pembrolizumab-expected-in-h1-and-q4-2025-phase-12-trial-for-wtx-330-to-begin-in-q1-2025-cash-runway-through-q2-2026
Werewolf Therapeutics Outlines 2025 Milest...
01/13/2025 13:51:26

– Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to gui...

hc-wainwright--co-reiterates-buy-on-werewolf-therapeutics-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on Were...
11/19/2024 11:27:57

HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15...

werewolf-therapeutics-q3-eps-038-beats-041-estimate
Werewolf Therapeutics Q3 EPS $(0.38) Beats...
11/07/2024 14:14:57

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of...

werewolf-therapeutics-unveils-preclinical-and-clinical-data-at-sitc-meeting-highlighting-tumor-activated-il-12-prodrug-wtx-330s-efficacy-and-tolerability-in-phase-1-trials-alongside-anti-tumor-potency-of-indukinetm-molecules
Werewolf Therapeutics Unveils Preclinical ...
11/07/2024 14:04:43

werewolf-therapeutics-announces-promising-new-development-candidate-wtx-921-a-first-of-its-kind-il-10-indukine-molecule-for-inflammatory-diseases
Werewolf Therapeutics Announces Promising ...
10/31/2024 12:29:00

Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical compan...

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
10/22/2024 16:30:56

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION